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Purpose or Objective: Margin-directed neoadjuvant 
pancreatic cancer radiotherapy aims to improve rates of 
surgical resection with clear margins. The target volume 
encompasses adjacent/infiltrated vasculature but methods 
used in its definition have varied and in some cases lacked 
reproducibility. SPARC (UKCRN ID: 18496) is a CRUK-funded 
[grant number C43735/A18787] phase 1 study of pre-
operative Margin-Intense Stereotactic Radiotherapy for 
patients with Borderline-Resectable Pancreatic Cancer 
(BRPC) and incorporates a comprehensive Radiotherapy 
Quality Assurance protocol to ensure consistency in target 
definition and radiotherapy delivery. 
 
Material and Methods: On a BRPC test case ‘Gold-Standard’ 
structures were defined by two clinical oncologists and one 
radiologist. A detailed method was specified for derivation of 
CTV_M, the target structure for the margin-directed boost. 
GTV_T was contoured to define gross tumour. Conformity 
analysis metrics were generated to compare structures 
produced independently by six clinical oncologist 
investigators with the Gold-Standard. 
 
 
Results: Gold-Standard and median investigator volumes for 
GTV_T were 2.1cc and 5.35cc (IQR 4.1-6.7) respectively, and 
1.1cc and 1.3cc (IQR 0.9-1.5) for CTV_M. Median distance 
between centre of mass of Gold-Standard and investigator 
volumes was 0.32cm (0.19-0.47cm) for GTV_T and 0.24cm 
(0.09-0.36cm) for CTV_M. Median DICE conformity 
coefficients for GTV_T and CTV_M were 0.51 (0.40-0.60) and 
0.68 (0.60-0.75), median discordance indices (measurement 
of over-inclusive contouring) for GTV_T and CTV_M were 0.64 
(0.54-0.74) and 0.39 (0.19-0.44). 
 
Conclusion: The investigator CTV_M structures showed less 
inter-observer variance in volume and less deviation from the 
Gold-Standard compared with the investigator GTV_T 
structures. The method of CTV_M definition appears 
consistently reproducible but accurate delineation of 
pancreatic malignancies remains difficult and oncologists 
should have expert radiology support in this task. 
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Purpose or Objective: Adjuvant radiotherapy (RT) is 
frequently used in the treatment of biliary tract cancer 
(BTC). Accurate target volume delineation is crucial for 
tumor control and avoiding unnecessary damages. However, 
there is no consensus on delineation of clinical target volume 
(CTV) in BTC. The aim of our study is to review the published 
details of the CTV contouring practice and to propose criteria 
for the CTV delineation in the adjuvant RT of BTC. 
 
Material and Methods: A comprehensive literature search 
was performed using the ‘‘PubMed’’ and ‘‘Google Scholar’’ 
databases, and articles on BTC radiotherapy that provided 
descriptions of the CTV contouring were selected. The 
descriptions were thoroughly reviewed and compared to 
identify the areas of strong consensus on their inclusion in 
the CTV among different authors and the areas with more 
variability that require individual decisions when creating the 
CTV. Nodal CTV was considered as well as the microscopic 
tumor spread (MTS) into the liver and along the bile-duct 
system. Three types of BTC were considered: intrahepatic 
cholangiocarcinoma (IHC), extrahepatic cholangiocarcinoma 
(EHC) and gall bladder cancer (GBC). Based on the analyzed 
data on contouring practice, we proposed a set of guidelines 
for the CTV delineation. 
 
Results: Out of 52 studies that reported the use of adjuvant 
RT in BTC, 17 were finally included: one prospective, 13 
retrospective and 3 reviews. 1. EHC and GBC (14 relevant 
studies): the porta hepatic and celiac lymph nodes (LN) were 
always included into the CTV (100% accordance), the 
pancreaticoduodenal LN were included in all but one study 
(93%), whereas for paraaortic LN no agreement exists: four 
authors (28.5%) mentioned them to be included. Additionally, 
one author (7%) included the superior mesentery artery nodes 
for ampullary location. Some data regarding the MTS was 
reported in three studies: tumor bed was encompassed with 1 
cm, 1-1.5 cm and 2-3 cm margin, respectively. One author 
mentioned 2-4 cm margin to account for MTS along the bile 
duct. 2. IHC (3 studies): a strong consensus (100% 
accordance) exists on including the porta hepatic, celiac and 
pancreaticoduodenal LN into the CTV. Only one author 
mentioned the para-aortic LNS to be included. Regarding the 
MTS: two authors used 1 cm margin to cover the tumor bed 
and resection margin of liver and one author mentioned 2-4 
cm margin to account for MTS along the bile duct. 
 
Conclusion: 
 
 
This is the first proposal of the CTV contouring guidelines for 
adjuvant RT for BTC. We recommend the coverage of porta 
hepatic, celiac and pancreaticoduodenal LN in all cases of 
BTC. Para-aortic LN coverage should be considered especially 
in EHC and GBC, and its use should be individualized. Tumor 
bed and resection margin of liver should be encompassed 
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with at least 1cm margin. In view of considerable variability 
between different authors, there is an obvious need for the 
international consensus guidelines. 
 
Poster: Clinical track: Lower GI (colon, rectum, anus)  
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Purpose or Objective: Aim of this clinical study was to 
evaluate resectability and pathological response after 
preoperative concurrent chemotherapy with 2 different drugs 
and radiation therapy (RT) intensified with concomitant 
boost. 
 
Material and Methods: A clinical trial based on two-stage 
Simon’s design was planned. The trial included a first phase 
with enrolment of 9 patients. If 0/9 patients had complete 
pathologic response (pCR) the study had to be closed. In case 
of ≥ 1/9 patients with pCR it was planned to enrol other 8 
patients. RT was performed with 3D-conformal technique. 
The dose to mesorectum and pelvic lymph nodes was 45 Gy 
(1.8 Gy/fraction). A concomitant boost was delivered to GTV 
+ 2 cm margin with a total dose of 55 Gy (2.2 Gy/fraction). 
The following concurrent chemotherapy was administered: 
Raltitrexed (3 mg/m2) and Oxaliplatin (130 mg/m²) on days 
1, 17, 35 of RT. Acute and late toxicities were evaluated 
according to CTC-AE v.3.0 criteria. 
 
Results: All 9 patients enrolled in the 1st phase underwent 
radical surgical resection, with 4/9 pCR. Then, 9 additional 
patients were enrolled for a total of 18 patients (F: 8, M: 10; 
median age 64.5, range: 45-80; clinical stage: 2 local 
recurrences, 16 cT4, 6 cN0, 4 cN1, 7 cN2, 1 cN3). Seventeen 
patients underwent surgical resection (7 anterior resections 
and 9 abdominal-perineal amputation) while 2 patients did 
not undergo surgery for early metastatic progression (1) or 
surgery refusal (1). R0 resection was achieved in all patients 
who underwent surgery. Overall, 5 patients had pCR and 2 
patients showed only microscopic residual disease (pT0-Tmic: 
7/17 = 41.2%). Acute grade ≥ 3 toxicity was: 1 leucopoenia -
neutropenia, 1 liver toxicity, 5 gastro-intestinal toxicities, 
with an overall incidence of 7/18 patients (38.9%). The 
actuarial analysis showed the following 2-year results: local 
control 100%, metastasis-free survival 93.7%, overall survival 
92.3%. 
 
Conclusion: The regimen used in this study allowed to 
achieve complete and near-complete response rate higher 
than 40%, despite the advanced stage of disease. However, 
severe acute toxicity was reported in more than 1/3 of 
patients. 
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Purpose or Objective: Aim of this analysis was to describe 
the results of a phase II study based on the use of VMAT in 
preoperative combined treatment of locally advanced rectal 
cancer. 
 
Material and Methods: A clinical trial based on two-stage 
Simon’s design was planned. The trial includes a 1st phase 
enrolment of 9 patients. If 0/9 patients had complete 
pathologic response (pCR) the study had to be closed. In the 
case of ≥ 1/9 patients with pCR it was scheduled to enrol 
other 8 patients. Radiation therapy was performed using 
VMAT-SIB technique. The dose to mesorectum and pelvic 
lymph nodes was 45 Gy (1.8 Gy/fraction). A concomitant 
boost was delivered on GTV + 2 cm margin with a total dose 
of 57.5 Gy (2.3 Gy/fraction). The following concomitant 
chemotherapy was administered: Capecitabine (825 mg/m² 
twice daily, 5 days/week) and Oxaliplatin (130 mg/m² on 
days 1, 17, 35). Acute and late toxicities were evaluated 
according to CTC-AE v. 3.0 criteria. 
 
Results: All 9 patients enrolled in the 1st phase underwent 
radical surgical resection, with 4/9 pCR. Then 9 additional 
patients were enrolled for a total of 18 patients (F: 7, M: 11; 
median age 62, range: 39-79); clinical stage: 4 local 
recurrences, 6 cT4, 5 cT3, 3 cT2, 2 cN0, 7 cN1, 9 cN2). 
Sixteen patients underwent surgical resection (9 anterior 
resection, 6 abdominal perineal amputations and 1 trans-anal 
resection) while 2 patients did not undergo surgery for early 
metastatic progression (1) or death from acute pulmonary 
oedema prior to surgery (1). R0 resection was achieved in all 
patients who underwent surgery. Overall, 4 patients had a 
pCR and 7 patients only a microscopic residual of disease 
(pT0-Tmic: 11/18 = 61.1%). Acute grade ≥ 3 toxicity was: 1 
leukopenia-neutropenia, 1 skin toxicity, 1 genitourinary 
toxicity and 5 gastrointestinal toxicities, with an overall 
incidence (considering the patient who died after radio 
chemotherapy) of 7/18 patients (38.9%). The actuarial 
analysis reported the following 2-year results: local control 
80%, metastasis-free survival 93.7%, overall survival 88.9%. 
 
Conclusion: The regimen used in this study showed excellent 
results in terms of pathologic responses (pT0-Tmic: 61.1%). 
However, despite the use of VMAT technique, more than 1/3 
of patients had severe acute toxicity. 
 
 
 
